Inghams Group (ASX: ING) — Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $0.16 — Trough / forward EPS (AUD)

0. Information Richness & AI Limitations

Grade A (mid-cap, but well covered), with heavy media attention (amplified by avian flu + an earnings shock). Note: ASX:ING is Inghams (Australian chicken), NOT the European ING bank. Core question: is ING an 'over-sold, new-CEO-turnaround, cheap chicken leader' deep-value opportunity, or a 'low-margin commoditized, supermarket-squeezed poultry producer + an H5N1 avian-flu black swan' value trap? Key facts: market cap down ~38% over the year, EPS −37%, 1H FY26 profit −65%; dividend cut 64% (11.0c → 4.0c — the trailing '8.6% yield' quoted elsewhere is stale; forward ~4.5%); net debt up to A$466.1M; H5N1 avian flu landed in Australia (June 2026) — WA operations locked down, shares fell 14% in a day (a structural tail risk for poultry producers).

1. Data & Cross-Validation

Price A$2.20; 371.68M shares; market cap A$818M (verified 0.00%); PE(TTM) 14.5x, forward 12.6x; EPS TTM A$0.15 (FY25 was 0.24 — sharp decline); dividend cut 64% (11c→4c interim), forward yield ~4.5% (NOT the stale trailing 8.6%); net debt A$466.1M (rising); analyst Hold, target A$2.39.

5-year trend (AUD, FY ends late June): revenue A$2,669→3,152M; net income A$83→35→60→101 (FY24 peak)→90 (FY25) — low-margin (operating margin 3.7-7%) and highly volatile (FY22 collapsed to A$35M/EPS 0.09 on feed-cost inflation); TTM further dropped to ~A$56M/EPS 0.15 (Woolworths loss + costs); FCF positive but declining (A$212M FY25). FY26 EBITDA guidance A$180-200M (cut from A$215-230M) — reflecting the Woolworths hit. The distress: lost/renegotiated a big Woolworths supply contract (Woolworths retail volume −16.1% in 1H FY26; replacing ~3/4 via other retail + QSR); new CEO Edward Alexander (ex-NZ CEO, from June 2025); turnaround plan targets A$130M EBITDA uplift over 3 years.

2. Business Essence — Duan Yongping

One line: Australia's largest 'chicken factory' — a vertically-integrated poultry producer (feed → breeding → hatchery → growing → processing → further processing), wholesaling commoditized chicken to two supermarket giants and QSR chains, earning thin, feed-cost-volatile, big-customer-dependent 'hard money'; the upside is that chicken is the cheapest protein — defensive and structurally growing demand.

Strengths: defensive + structural demand (chicken is the cheapest animal protein, benefits in downturns as consumers trade down from red meat, per-capita consumption rising long-term); scale + vertical integration (~40%+ Australian share, full chain, clear cost advantage); cheap + turnaround option (12.6x forward, market cap only A$818M (down 38%), big earnings elasticity if the A$130M EBITDA turnaround delivers); NZ bright spot (NZ volume +5.2%).

But (why it crashed): no pricing power, squeezed by the supermarket duopoly (Woolworths/Coles control retail; the Woolworths volume cut is living proof of the bargaining imbalance — Duan's most-disliked 'the customer is far more powerful than you'); slave to feed costs (feed is 60-70% of COGS — grain/soy price spikes (like FY22) instantly eat the thin margin); H5N1 avian-flu black swan (landed in Australia, and a large outbreak → culling, plant shutdowns, biosecurity costs — a structural fat left tail for poultry producers); leverage up (net debt A$466M, interest pressure + dividend cut 64% in distress); low-margin commodity (a thin-margin agri-processing business).

Duan's verdict: NOT the 'right business' Duan likes — low-margin, no pricing power, customer-concentrated, weather/disease-dependent. Duan: selling chicken to two supermarkets far more powerful than you, earning feed-swung hard money, and it can hit avian flu anytime — I don't like the business itself. It's cheap because it's in trouble. A 'cigar-butt' distressed turnaround, not a good company; only if the price is cheap enough and you believe the new management can turn it around is it worth a small bet.

3. Moat — Buffett

Brand/pricing ★☆☆☆☆ (chicken is a commodity, pricing power is in the supermarkets' hands (the Woolworths loss proves it), almost no ability to raise price); switching costs ★★☆☆☆ (some friction for supermarket/QSR customers to switch suppliers (supply chain, certification), but replaceable — Woolworths cut volume anyway); network effects ☆; scale ★★★★☆ (core moat — ~40%+ Australian share, vertically-integrated full chain, huge growing/processing capacity, clear unit-cost advantage — the biggest barrier); technical/biosecurity ★★☆☆☆ (breeding, biosecurity, further-processing know-how, but no hard patent; and avian flu exposes biosecurity fragility).

Trend: scale moat stable, but the pricing-power moat narrowing (the Woolworths loss shows falling bargaining power vs supermarkets). Buffett question: the scale/vertical-integration moat likely persists 10 years out (Australians still eat chicken, ING's capacity + share hard to dislodge). Threats: (1) continued supermarket-duopoly price pressure (structural, long-term); (2) a large H5N1 outbreak (culling/shutdown, even human-transmission in the extreme); (3) chronically high feed costs; (4) plant-based/cultured protein long-term substitution (slow variable). The moat is 'scale,' not 'pricing power' — in an industry dominated by duopsony buyers, a scale moat can preserve survival but not high returns.

4. Reverse Thinking & Risks — Munger

Analogies: cautionary — protein commodity stocks (US Pilgrim's Pride, Tyson) swing violently through avian-flu/feed cycles — commodity protein is famously cyclical + disease-sensitive + thin-margin, and avian flu has hurt many producers historically. Neutral — successful distressed turnarounds exist too: if the new management's value-led strategy + feed-cost normalization + no major outbreak, earnings can recover meaningfully from the trough (as FY22→FY24 NPAT recovered A$35M→A$101M) — ING itself has shown strong cyclical rebounds. Munger (cycle + tail risk): ING is governed by both the feed cycle (mean-reverting) and the avian-flu tail (unpredictable, destructive). Munger stresses 'avoid risks that can wipe you out' — H5N1 is exactly that low-probability, high-destruction fat left tail; even if cheap, you must demand extra margin of safety for that tail and control position size. Munger question / why avoid or short: a no-pricing-power, duopsony-squeezed, thin-margin, highly-cyclical commodity business with an avian-flu black swan overhead, and an unproven new-CEO turnaround. Skeptics: '12.6x looks cheap, but earnings are falling, the dividend is cut, net debt is rising, and it can be hit by avian flu anytime — cheap for good reason; I'd wait for the turnaround to be proven, or demand a much cheaper price to compensate for the fat tail.'

5. Management — Duan Yongping + Buffett

Assessment: new CEO, turnaround unproven — Ed Alexander is ~1 year in, internally seasoned (strong NZ results, NZ volume +5.2%), but group-level distressed-turnaround execution needs validation — one of the biggest uncertainties. Prudent decisions, no governance flaw (cutting the dividend to protect the balance sheet, diversifying customers = responsible distress management; transparent disclosure); Buffett integrity light: acceptable (green-tinged-amber). But management can't control the decisive variables — feed costs, supermarket bargaining, avian flu are largely outside its control.

Duan question: if the CEO retires, does it stay competitive? At the scale/capacity level yes (the moat is assets, not the person), but it's in a critical turnaround phase, heavily dependent on the new management's execution. If the turnaround aborts, it reverts to a 'thin-margin commodity' baseline. This is a 'people (new CEO) + thing (turnaround) both unclear' stage.

6. Industry & Civilizational Trend — Li Lu

Not a paradigm shift. Poultry farming is an ancient, mature, cyclical agri-processing sector. Demand trend (positive): chicken is the cheapest, most efficient animal protein — global + Australian per-capita consumption rising long-term, substituting red meat — real, defensive, structural demand (benefits in downturns). Supply/risk trend (negative): H5N1 avian flu is spreading globally and has landed in Australia, ending Australia's 'avian-flu-free' status — a civilizational-scale biosecurity threat, a sword hanging over poultry producers (culling, rising biosecurity spend, even the extreme tail of human transmission). Value-chain position: the 'protein production layer' of the food chain — squeezed by upstream feed (grain) costs and downstream supermarket duopoly, earning a thin scale-processing fee in the middle. A structurally weak position. Substitution (slow variable): plant-based/cultured protein may divert some demand long-term, but limited near-to-medium-term impact on cheap real chicken. Li Lu question: a 'cross-cycle producer of cheap national protein, utility-like agri-processor' — it won't disappear (people always need cheap protein), but its ceiling is locked by no pricing power + feed cycle + supermarket duopoly + disease risk. A necessary-but-weak link in the food supply chain, stable but hard to earn excess returns, plus an avian-flu fat left tail. The weakest value capture + worst risk profile of the 13 (adequate civilizational position for cheap-protein demand, but a supermarket-squeezed, disease-exposed weak link).

7. Valuation & Scenarios — Buffett + Duan

Forward PE 12.6x / forward yield ~4.5% fully franked (note the trailing 8.6% is stale — cut 64%). Reverse-read: 12.6x forward is built on already-cut FY26 earnings (EBITDA A$180-200M) — the market prices 'continued distress, turnaround undecided.' If the A$130M EBITDA turnaround delivers + feed is benign + no major outbreak, deeply undervalued; if the turnaround aborts or avian flu erupts, a value trap. Vs history: earnings at a trough (EPS from 0.27 to 0.15); the recovery elasticity comes from earnings recovery, not the multiple. Vs peers: global protein commodity stocks (Tyson/Pilgrim's) trade single-digit-to-low-teens at cycle bottoms; ING at 12.6x forward is fair, with the turnaround option not fully priced but the tail risk real.

Three scenarios (base trough EPS A$0.16, tool-verified):

3-year: Bull 20% growth / 14x → A$3.9 (+76%, 25%); Base 8% / 12x → A$2.4 (+10%, 40%); Bear −3% / 9x → A$1.3 (−40%, 35%). Prob-weighted ≈ A$2.4 (+9%). 5-year: Bull → A$5.6 (+153%, 30%); Base → A$2.8 (+28%, 40%); Bear → A$1.2 (−44%, 30%). Prob-weighted ≈ A$3.2 (+44%).

⚠️ High dispersion, fat left tail: widest dispersion + fattest left tail of the group — 3yr bear −40%, 5yr bear −44%, and this does NOT fully price a large-scale H5N1 outbreak (which could halve the stock beyond the model). Prob-weighted 3yr only +9% (dragged by the heavy 35% bear weight), 5yr +44% (the turnaround has time). The keys: two 'deliveries' + one 'non-event' — the A$130M EBITDA turnaround delivers; feed benign + customer volume recovers; no large-scale avian-flu outbreak. Downside has no NTA floor; the cheap multiple + ~4.5% dividend + defensive chicken demand only partly cushion.

Duan question ('hold 5 years?'): only in a very small position, understanding it's a speculative turnaround. Cautious positives: chicken demand defensive + structural, scale leader hard to topple; cheap + turnaround option, 5-year prob-weighted +44%; responsible management response (dividend cut, customer diversification). But strong reservations: no pricing power, supermarket-squeezed, feed cycle, avian-flu fat left tail, unproven turnaround — does NOT meet the 'lights-out for 5 years' bar. Duan: this isn't a good business I want to hold long — too much is out of its control, and there's an avian-flu blade overhead. If I touch it, a very small position as a cheap, decent-odds distressed turnaround — never bet the house.

8. Decision Memo

Decision: No position: small, speculative (distressed-turnaround) position only, NOT a core holding. At A$2.20 (down 38%, 12.6x forward, ~4.5% forward yield) cheap with a A$130M turnaround option, but no pricing power + an avian-flu fat left tail demand strict position control. Size small (wide dispersion, downside −40%+ with no asset floor); track turnaround KPIs (EBITDA repair, non-Woolworths volume, feed costs) + avian-flu developments; ideal buy is 'turnaround shows early results while the stock is still low,' or a cheaper price (A$1.8-2.0) to compensate the fat tail. Those averse to black swans / no-pricing-power businesses may reasonably avoid entirely. Hold or trim: if you believe the new CEO's turnaround and can bear the avian-flu tail, hold a small position for a 5-year turnaround; if you can't bear the fat tail or need steady income (dividend cut 64%), trimming into strength is safer. Sell signals: a large-scale H5N1 outbreak in its growing regions (can veto the thesis); turnaround stalls, EBITDA persistently below the A$180M guidance floor; supermarkets cut volume/price further; feed-cost blowout (FY22 repeat); dividend cut again. Add signals: turnaround delivers toward the A$130M EBITDA uplift, non-Woolworths volume + margin improve; feed costs ease, no outbreak, biosecurity holds; price A$1.8-2.0 (thicker margin of safety); consumer-lending... (n/a) — record chicken volume with controlled costs.

One-line conclusion: an 'over-sold, cheap, but structurally weak (no pricing power + supermarket-squeezed + feed cycle), with an H5N1 avian-flu fat left tail overhead' distressed turnaround / special situation. The weakest business quality and worst risk profile of the 13. Not the REITs'/HVN's 'NTA floor,' not WTC/XRO's 'crashed quality growth' — a 'cigar-butt distressed turnaround + tail bet': cheap (12.6x forward), with a A$130M turnaround option + defensive chicken demand, at the cost of no pricing power, supermarket bargaining, feed volatility, and an avian-flu black swan. ⚠️ Note the dividend is cut 64% — the trailing 8.6% yield is stale/misleading, forward only ~4.5%. Prob-weighted 3-year ≈ A$2.4 (only +9%, dragged by a heavy bear weight, ~7%/yr incl dividend); 5-year ≈ A$3.2 (+44%, turnaround has time, ~12%/yr); bull (turnaround delivers + no outbreak) 5-year A$5.6 (+153%); bear (turnaround stalls) A$1.2-1.3 (−40 to −44%), and a large-scale avian-flu outbreak would be deeper (beyond the model). Widest dispersion of the group. Only for aggressive/special-situation investors who can bear high volatility + a black swan and speculate a turnaround with a small position; for those seeking certainty, steady income, or averse to tail risk, avoiding entirely is perfectly rational.

Four-Master Commentary

Buffett: "I like a business with scale, and Inghams has scale in Australian chicken. But it sells a commodity to two supermarkets far more powerful than it, with no pricing power — the situation I dislike most. Add a risk that can wipe you out overnight — avian flu — and even cheap, I'd be very careful, or just put it in the 'too-hard' pile."

Munger: "Reverse it — how do I lose everything? A large-scale avian-flu outbreak. That's the low-probability, high-destruction fat left tail I've spent my life avoiding. The business has no pricing power and watches feed costs. Cheap it may be, but a cheap cigar butt can be poisonous. If I touch it, the position must be small enough that a zero doesn't hurt."

Duan Yongping: "Selling chicken to supermarkets, earning hard money, at the mercy of the weather (feed), the customer (supermarkets), and luck (disease) — this isn't the 'right business' I want. It's cheap now, with a turnaround story, but too much is out of its control. If I bet, a very small position on the turnaround — never the house."

Li Lu: "People will always eat cheap protein, chicken demand is defensive and growing, and this national chicken factory is probably still here in 20 years. But it's squeezed on both sides of the chain, with an avian-flu blade overhead — destined to be a necessary but weak link: alive across cycles, but hard to earn excess returns, and carrying a black swan. It's ballast, not an engine — and this ballast has a crack."